Anthony Chinemere Anuforo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anthony Chinemere Anuforo has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Aaron O Aboderin
1 shared publicationAbhilasha Karkey
1 shared publication- Abhilasha Sharma1 shared publication
- Adedayo Hakeem Oyebanji
Cardiac Centre, Babcock University Teaching Hospital (BUTH), Ilisan-Remo, Nigeria
1 shared publication - Adekemi Kiyesi
Department of Chemical Pathology, Afe Babalola Multi-System Hospital, Ado-Ekiti, Nigeria
1 shared publication Aderemi Oludiran Kehinde
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in The Lancet Microbe
Evaluation of the laboratory assessment process for A Clinically Oriented Antimicrobial Resistance Surveillance Network (ACORN-LAP) in low-income and middle-income countries: a multicountry, cross-sectional analysis with longitudinal quality monitoring
- 29 September 2026
- Published by Elsevier in The Lancet Microbe
Open AccessEvaluation of the laboratory assessment process for A Clinically Oriented Antimicrobial Resistance Surveillance Network (ACORN-LAP) in low-income and middle-income countries: a multicountry, cross-sectional analysis with longitudinal quality monitoring
- Open Access
- 30 July 2025
- Published by Maad Rayan Publishing Company in Journal of Research in Clinical Medicine
- Vol. 13 (1) , 34477
Investigating an unusual rise in blood-borne coagulase-negative Staphylococci in a tertiary health facility, Southwest Nigeria
Introduction: The clinical significance of coagulase-negative staphylococci (CoNS) is becoming increasingly concerning in healthcare settings, with dire consequences such as mortality. We investigated an unusual increase in blood-borne CoNS among patients in a private tertiary health facility in Southwest Nigeria and described mitigation strategies. Methods: CoNS bacteraemia descriptive analysis was conducted among inpatients between April 2022 and June 2022. Blood cultures were processed with an automated system. Phenotypic and molecular analyses (using 16S rDNA) of CoNS were performed according to established guidelines. We implemented the multimodal infection prevention and control (IPC) approach recommended by the World Health Organisation. Results: Eighty-two blood cultures (non-duplicate samples) were requested during the period. Of these, 30 (36.5%) were culture-positive, and 10 were CoNS (10/30, 33.3%).The cumulative incidence of CoNS bacteraemia was 12 cases per 100 patients over 90 days, compared to 1-2% in previous months. Staphylococcus haemolyticus (4/10, 40%), Staphylococcus hominis (3/10, 30%), Staphylococcus epidermidis (2/10, 20%), and Staphylococcus saccharolyticus (1/10, 10%) were identified. All isolates were resistant to ciprofloxacin, trimethoprim-sulfamethoxazole, and cefoxitin (methicillin-resistant surrogate marker), while they were susceptible to vancomycin and linezolid. All the isolates fell into the S. epidermidis and S. haemolyticus clusters in phylogenetic studies. The rates returned to baseline following the implementation of the IPC strategies. Conclusion: The unusual surge in CoNS incidence at the hospital resulted from multidrug-resistant clusters of S. haemolyticus and S. epidermidis, which were addressed by the implementation of multimodal IPC strategies.
- 30 July 2025
- Published by Maad Rayan Publishing Company in Journal of Research in Clinical Medicine
- Vol. 13 (1) , 34477
Open AccessInvestigating an unusual rise in blood-borne coagulase-negative Staphylococci in a tertiary health facility, Southwest Nigeria
Introduction: The clinical significance of coagulase-negative staphylococci (CoNS) is becoming increasingly concerning in healthcare settings, with dire consequences such as mortality. We investigated an unusual increase in blood-borne CoNS among patients in a private tertiary health facility in Southwest Nigeria and described mitigation strategies. Methods: CoNS bacteraemia descriptive analysis was conducted among inpatients between April 2022 and June 2022. Blood cultures were processed with an automated system. Phenotypic and molecular analyses (using 16S rDNA) of CoNS were performed according to established guidelines. We implemented the multimodal infection prevention and control (IPC) approach recommended by the World Health Organisation. Results: Eighty-two blood cultures (non-duplicate samples) were requested during the period. Of these, 30 (36.5%) were culture-positive, and 10 were CoNS (10/30, 33.3%).The cumulative incidence of CoNS bacteraemia was 12 cases per 100 patients over 90 days, compared to 1-2% in previous months. Staphylococcus haemolyticus (4/10, 40%), Staphylococcus hominis (3/10, 30%), Staphylococcus epidermidis (2/10, 20%), and Staphylococcus saccharolyticus (1/10, 10%) were identified. All isolates were resistant to ciprofloxacin, trimethoprim-sulfamethoxazole, and cefoxitin (methicillin-resistant surrogate marker), while they were susceptible to vancomycin and linezolid. All the isolates fell into the S. epidermidis and S. haemolyticus clusters in phylogenetic studies. The rates returned to baseline following the implementation of the IPC strategies. Conclusion: The unusual surge in CoNS incidence at the hospital resulted from multidrug-resistant clusters of S. haemolyticus and S. epidermidis, which were addressed by the implementation of multimodal IPC strategies.